De-connect protein variant and pharmaceutical use thereof

The present invention discloses and de-connect protein variant and pharmaceutical use thereof.The described protein variant that de-connects comprises having integrin av beta 3 receptor-antagonist activities and de-connecting albumen with wild type and compares the active isolated polypeptide that reduces greatly of integrin aIIb β 3 and/or a5 β1Shou Ti-blocking-up.The modification of the amino acid sequence that this variant is modified by coding to de-connect the pyrenoids nucleotide sequence coded, cause this polypeptide and wild type to de-connect the compatibility that albumen compares integrin aIIb β 3 and/or a5 β 1 and significantly reduce.Described variant can be used for treating and/or preventing in the mammal and the relevant disease of av β 3 integrins, and it comprises relevant eye disease, Paget disease, rheumatic arthritis and the osteoarthritis of hypercalcinemia, angiogenesis that metastases, malignant tumour are induced in the relevant tumor growth of osteoporosis, bone tumour or cancer growth, angiogenesis and transfer, the bone.The eye disease that angiogenesis is relevant comprises that AMD, diabetic retinopathy, cornea rebirth blood vessel form neovascularization retinopathy, high myopia and retinopathy of prematurity that disease, ischaemic are induced.